

## **CURRICULUM VITAE (updated to May 08, 2018)**

Name: Matteo Franchi

Date of Birth: 07/12/1986

Place of Birth: Milano (MI), Italy

Citizenship: Italian

Address: Via Bellini 18/C, 22078 Turate (CO), Italy

Work Address: Laboratory of Healthcare Research and Pharmacoepidemiology,  
Department of Statistics and Quantitative Methods,  
University of Milan-Bicocca,  
Via Bicocca degli Arcimboldi 8 (Building U7, Second floor),  
20126 Milan, Italy

Phone: +39.02.64485859

Mobile Phone: +39.3405154712

E-mail: [matteo.franchi@unimib.it](mailto:matteo.franchi@unimib.it)

Education: January 2014 – December 2016: Doctoral student in “Public Health”  
(XXIX cycle), University of Milano-Bicocca, Milan

October 2012 – October 2013 – Vocational training in “Biomedical  
Research Specialist” –Mario Negri Institute, Milan

March 2013 – Second Level Degree in Biostatistics – University of  
Milano-Bicocca, Milan (107/110)

June 2010 – First level Degree in Statistical Sciences – University of  
Milano-Bicocca, Milan (98/110)

Research Experience: January 2014 – present. Laboratory of Healthcare Research and  
Pharmacoepidemiology, Department of Statistics and Quantitative  
Methods, University of Milano-Bicocca, Milan.

April 2015 – December 2015. International Prevention Research Institute  
(iPRI), Lyon, France.

February 2011 – December 2015. Mario Negri Institute, Milan -  
Department of Epidemiology.

September 2010 - January 2011. Centro Studi GISED, Bergamo at Mario Negri Institute, Milan.

January 2010 – April 2010. Mario Negri Institute, Milan - Department of Epidemiology.

Main fields of interest: Pharmacoepidemiology: conduction of observational studies using both healthcare utilization databases and population-based registry databases for the evaluation of pharmacoutilization, effectiveness and safety of drugs mainly used for the treatment of oncologic and diabetic diseases. Evaluation of diagnostic and therapeutic pathways of patients diagnosed with cancer.

I currently coordinate the Italian multiregional project “Farmaci Biologici in Oncologia (FABIO)”, supported by the Italian Drug Agency (AIFA).

I coordinated the Italian multiregional project “Generating Real World Evidence on the Treatment of metastatic colorectal cancer with Avastin-bevacizumab (GRETA)”.

I currently have been involved in the following international projects:

- “Post-authorization safety study (PASS) of GLP-1 Receptor Agonists and Risk of Acute Pancreatitis, Pancreas Cancer and Medullary Thyroid Cancer”;
- “Prospective cohort study of long-term safety of teriflunomide in multiple sclerosis patients in Europe”;
- “Establishing an external comparison cohort study (ECCS) for the post-authorization safety study (PASS) on alemtuzumab treatment in European multiple sclerosis patients”.

Teaching experience:

Academic year 2017-2018:

- Teaching assistant of the course of “Medical Statistics” (undergraduate course in Statistics, University of Milano-Bicocca).
- Teaching assistant of the course of “Methodology of clinical and epidemiological research and pharmacoepidemiology” (postgraduate course in Statistics, University of Milano-Bicocca).
- Teaching assistant of the course of “Biostatistics” (postgraduate course in Biology, University of Milano-Bicocca).

Academic year 2016-2017:

- Teaching assistant of the course of “Medical Statistics” (undergraduate course in Statistics, University of Milano-Bicocca).

Other:

- I am the co-director of the second-level Master in “Pharmacoepidemiology and Healthcare Research” for the year 2018-2019.

Technical skills: Statistical software: SAS, R, STATA, SPSS.

Languages: Italian: mother tongue  
English: good  
French: elementary

Scientific affiliations: Member of the *Italian Society of Medical Statistics and Clinical Epidemiology* (SISMEC).  
Afferent to the Interuniversity Centre of *Healthcare Research & Pharmacoepidemiology*.

Other: Reviewer of the following scientific journal: *Tumori Journal and Epidemiology, Biostatistics and Public Health (EBPH)*

Bibliometric indexes: To date, I am Author / Co-author of 17 papers (Source: PUBMED) with 204 total citations and H-index = 8 (Source: Google Scholar).

#### Published articles:

1. Carioli G, Bonifazi M, Rossi M, Zambelli A, **Franchi M**, Zocchetti C, Gasparini S, Corrao G, La Vecchia C, Negri E. Management and Survival of Pleural Mesothelioma: A Record Linkage Study. *Respiration*. 2018 Feb 8. [Epub ahead of print]
2. Scotti L, **Franchi M**, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. *Semin Arthritis Rheum*. 2018 Jan 6. [Epub ahead of print]
3. Boniol M, **Franchi M**, Bota M, Leclercq A, Guillaume J, van Damme N, Corrao G, Autier P, Boyle P. Incretin-Based Therapies and the Short-Term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies. *Diabetes Care*. 2018 Feb;41(2):286-292
4. Corrao G, Monzio Compagnoni M, **Franchi M**, Cantarutti A, Pugni P, Merlino L, Catapano AL, Mancia G. Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation. *Eur J Intern Med*. 2018 Jan;47:25-31
5. Cantarutti A, **Franchi M**, Monzio Compagnoni M, Merlino L, Corrao G. Mother's education and the risk of several neonatal outcomes: an evidence from an Italian population-based study. *BMC Pregnancy Childbirth*. 2017 Jul 12;17(1):221
6. Parazzini F, **Franchi M**, Tavani A, Negri E, Peccatori FA. Frequency of Pregnancy Related Cancer: A Population Based Linkage Study in Lombardy, Italy. *Int J Gynecol Cancer*. 2017 Mar;27(3):613-619

7. **Franchi M**, Ascitutto R, Nicotra F, Merlino L, La Vecchia C, Corrao G, Bosetti C. Metformin, other antidiabetic drugs, and endometrial cancer risk: a nested case-control study within Italian healthcare utilization databases. *Eur J Cancer Prev.* 2017 May;26(3):225-231
8. Rossi M, Carioli G, Bonifazi M, Zambelli A, **Franchi M**, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. *Eur J Cancer.* 2015 Nov 26;52:41-49
9. Bosetti C, **Franchi M**, Nicotra F, Ascitutto R, Merlino L, La Vecchia C, Corrao G. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. *Pharmacoepidemiol Drug Saf.* 2015 Jul;24(7):771-8
10. Negri E, Zambelli A, **Franchi M**, Rossi M, Bonifazi M, Corrao G, Zambon A, Moja L, Zocchetti C, La Vecchia C. Effectiveness of Trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study. *Oncologist.* 2014 Dec;19(12):1209-15
11. Bonifazi M, **Franchi M**, Rossi M, Zambelli A, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice. *Breast.* 2014 Oct;23(5):573-8
12. Mazzucco W, Rossi M, Cusimano R, **Franchi M**, Bonifazi M, Mistretta A, Vitale F, Ricciardi W, Negri E, Boccia S, La Vecchia C. Use of trastuzumab for breast cancer: the role of age. *Curr Pharm Des.* 2014;20(38):5957-62.
13. Rossi M, Edefonti V, Parpinel M, Lagiou P, **Franchi M**, Ferraroni M, Decarli A, Zucchetto A, Serraino D, Dal Maso L, Negri E, La Vecchia C. Proanthocyanidins and other flavonoids in relation to endometrial cancer risk: a case-control study in Italy. *Br J Cancer.* 2013 Oct 1;109(7):1914-1920
14. Negri E, Rossi M, Bonifazi M, **Franchi M**, Carioli G, Zocchetti C, Corrao G, La Vecchia C. Clinical use, safety and effectiveness of novel high cost anticancer therapies after marketing approval: a record linkage study. *Epidemiology Biostatistics and Public Health.* 2013; 10(3): e9016-1 – e9016-8.
15. Bonifazi M, **Franchi M**, Rossi M, Moja L, Zambelli A, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. *Oncologist.* 2013;18(7):795-801
16. Muttarak R, Gallus S, **Franchi M**, Faggiano F, Pacifici R, Colombo P, La Vecchia C. Why do smokers start? *Eur J Cancer Prev.* 2013 Mar;22(2):181-6
17. Gallus S, Muttarak R, **Franchi M**, Pacifici R, Colombo P, Boffetta P, Leon ME, La Vecchia C. Why do smokers quit? *Eur J Cancer Prev.* 2013 Jan;22(1):96-101
18. Bonifazi M, Rossi M, Moja L, Scigliano VD, **Franchi M**, La Vecchia C, Zocchetti C, Negri E. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. *Oncologist* 2012; 17 : 117-124